Cellphire Therapeutics has stopped enrolling subjects in its CRYPTICS trial of CLPH-511 following feedback from an IDMC.

EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...

According to the WHO, meningitis is a significant global health threat even though treatments and vaccines against some forms ...

Contraception for women has seen little change over the past 50 years, with the most prevalent contraceptive pills containing ...

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

Daiichi and AstraZeneca's Enhertu with pertuzumab has shown PFS improvement in the Phase III DESTINY-Breast09 trial.

The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th ESCMID Global conference in Vienna, Austria.

Enlivex has completed the enrollment of all subjects in the Phase II stage of the Phase I/II trial of Allocetra for severe ...

Advarra has integrated its Center for IRB Intelligence (CIRBI) with the Study Collaboration for visibility into trial site ...

Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...